Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BCAX Bicara Therapeutics

盘后交易 07-09 18:00:29 EDT

9.67

+0.41

+4.43%

盘后9.67

+0.000.00%

17:49 EDT

最高9.93	最低9.30	成交量36.38万
今开9.31	昨收9.26	日振幅6.80%
总市值5.27亿	流通市值2.75亿	总股本5,454万
成交额351.74万	换手率1.28%	流通股本2,848万
市净率1.15	ROE-27.26%	每股收益-3.05
52周最高28.09	52周最低7.80	市盈率-3.17
股息0.00	股息收益率0.00	ROA-13.84%

北京优虎网络科技有限公司

{"stockData":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":9.67,"timestamp":1752091200000,"preClose":9.26,"halted":0,"volume":363789,"hourTrading":{"tag":"盘后","latestPrice":9.67,"preClose":9.67,"latestTime":"17:49 EDT","volume":5905,"amount":57108.282470000006,"timestamp":1752097748643},"delay":0,"floatShares":28482543,"shares":54536218,"eps":-3.051868,"marketStatus":"盘后交易","change":0.41,"latestTime":"07-09 18:00:28 EDT","open":9.31,"high":9.93,"low":9.3,"amount":3517408.176246,"amplitude":0.068035,"askPrice":9.91,"askSize":4,"bidPrice":8.14,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.051868,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1752105600000},"marketStatusCode":4,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":9.26,"preHourTrading":{"tag":"盘前","latestPrice":9.26,"preClose":9.26,"latestTime":"08:13 EDT","volume":12,"amount":110.97,"timestamp":1752063207806},"postHourTrading":{"tag":"盘后","latestPrice":9.67,"preClose":9.67,"latestTime":"17:49 EDT","volume":5905,"amount":57108.282470000006,"timestamp":1752097748643},"volumeRatio":0.71916,"impliedVol":0.3363,"impliedVolPercentile":0.25},"requestUrl":"/m/hq/s/BCAX","defaultTab":"news","newsList":[{"id":"2538446059","title":"核心药物试验数据亮眼 大摩维持Bicara Therapeutics(BCAX.US)“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2538446059","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538446059?lang=zh_cn&edition=full","pubTime":"2025-05-28 14:10","pubTimestamp":1748412642,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利分析师Judah Frommer在美国生物技术公司Bicara Therapeutics公布Ficerafusp alfa的1/1b期临床试验中期数据后，维持对该股的“买入”评级，目标价保持在36美元。Ficerafusp alfa作为该公司的核心资产，是一款具有首创性的双功能抗体药物。据了解，Bicara Therapeutics是一家专注于开发实体瘤创新疗法的临床阶段生物制药公司。Frommer认为，这一数据相较标准治疗方案是重大突破，预示着Ficerafusp alfa有望在这一治疗难度较大的领域取得里程碑式进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1298497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BCAX","LENZ"],"gpt_icon":0},{"id":"1104039039","title":"异动解读 | 分析师下调目标价，Bicara Therapeutics盘中大跌7.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104039039","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104039039?lang=zh_cn&edition=full","pubTime":"2025-05-16 21:33","pubTimestamp":1747402383,"startTime":"0","endTime":"0","summary":"周五盘中，生物科技公司Bicara Therapeutics股价出现大幅下跌，截至发稿时跌幅达7.29%，引发投资者关注。造成股价下跌的主要原因是投资银行H.C. Wainwright下调了对Bicara Therapeutics的目标价。据悉，H.C. Wainwright将该公司的目标股价从44美元下调至41美元，降幅达6.82%。对于生物科技公司而言，这可能与研发进展、临床试验结果或市场竞争等因素有关。投资者可能需要密切关注Bicara Therapeutics未来的公司公告和行业动态，以评估其长期投资价值。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"异动解读 | 分析师下调目标价，Bicara Therapeutics盘中大跌7.29%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCAX"],"gpt_icon":0},{"id":"2535722848","title":"Bicara Therapeutics(BCAX.US)：2025年Q1财报实现营收0美元；每股收益为-0.68美元，前值为-18.94美元，预期值为-0.38美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2535722848","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535722848?lang=zh_cn&edition=full","pubTime":"2025-05-13 19:41","pubTimestamp":1747136462,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics(BCAX.US)：2025年Q1财报实现营收0美元；每股收益为-0.68美元，前值为-18.94美元，预期值为-0.38美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/13194150355618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","BCAX"],"gpt_icon":0},{"id":"2484130309","title":"Bicara Therapeutics Inc.2024财年第三财季实现净利润-17.48百万美元，同比增加23.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484130309","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484130309?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:00","pubTimestamp":1732010416,"startTime":"0","endTime":"0","summary":"11月19日，Bicara Therapeutics Inc.公布财报，公告显示公司2024财年第三财季净利润为-17.48百万美元，同比增加23.50%；其中营业收入为0.00美元，每股基本收益为-0.32美元。机构评级：截至2024年11月19日，当前有4家机构对Bicara Therapeutics Inc.目标价做出预测，其中目标均价为42.05美元，其中最低目标价为36.00美元，最高目标价为48.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180024abcede94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180024abcede94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCAX","LENZ"],"gpt_icon":0},{"id":"1157360442","title":"异动解读 | TPG支持的生物科技公司Bicara Therapeutics首次公开募股(IPO)大涨45.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157360442","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157360442?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:16","pubTimestamp":1726247788,"startTime":"0","endTime":"0","summary":"9月13日,由风险投资巨头TPG支持的生物科技公司Bicara Therapeutics Inc在纳斯达克上市首日,股价大涨45.8%,引发投资者热捧。Bicara Therapeutics是一家专注于开发创新癌症疗法的生物科技公司。在本次IPO中,公司共发行了1320万股股票,融资2.25亿美元,超出了原计划规模。数据显示,今年美国的IPO市场复苏迹象明显,其中以医疗健康板块为重点领域。有分析认为,Bicara Therapeutics超额认购的成功上市预示着资金青睐具有前景的生物科技创新项目,为行业发展带来了新的契机。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCAX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bicara.com","stockEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":-0.1948},{"period":"3month","weight":-0.1096},{"period":"6month","weight":-0.3928},{"period":"1year","weight":-0.4856},{"period":"ytd","weight":-0.4684}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":0.0354},{"period":"3month","weight":0.1307},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.1172},{"period":"ytd","weight":0.0585}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Bicara Therapeutics Inc.于2018年12月12日在特拉华州注册成立。他们是一家临床阶段的生物制药公司，致力于为实体瘤患者带来变革性的双功能疗法。他们的主要项目阿法是一种双功能抗体，它结合了两个临床验证的靶点，即表皮生长因子受体（EGFR）导向的单克隆抗体和结合人类转化生长因子β（TGF-b）的结构域。通过这种双靶向机制，阿法有可能通过同时阻断癌症细胞固有的EGFR存活和增殖，以及肿瘤微环境（TME）中的免疫抑制性TGF-b信号传导，发挥强大的抗肿瘤活性。Ficerafusp alfa通过与肿瘤细胞上的EGFR结合，将TGF-b抑制剂直接引入TME，他们认为这将导致持久的反应和总生存率或OS的增加，同时减少通常与全身TGF-b抑制相关的不良反应。","exchange":"NASDAQ","name":"Bicara Therapeutics","nameEN":"Bicara Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Bicara Therapeutics(BCAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Bicara Therapeutics,BCAX,Bicara Therapeutics股票,Bicara Therapeutics股票老虎,Bicara Therapeutics股票老虎国际,Bicara Therapeutics行情,Bicara Therapeutics股票行情,Bicara Therapeutics股价,Bicara Therapeutics股市,Bicara Therapeutics股票价格,Bicara Therapeutics股票交易,Bicara Therapeutics股票购买,Bicara Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Bicara Therapeutics(BCAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}